Monte Rosa Therapeutics, Inc. GLUE Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow yield?
- Monte Rosa Therapeutics, Inc. (GLUE) reported free cash flow yield of -1.5% in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s free cash flow yield changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s free cash flow yield decreased by 114.0% year-over-year, from 10.7% to -1.5%.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s free cash flow yield?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s free cash flow yield has grown at a -28.2% compound annual growth rate (CAGR), from -7.3% to -2.7%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.